Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2020-12-31 Capital/Financing Update
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the exercise and closing of an over-allotment option related to a public offering of units by Avicanna Inc. It details the number of units issued, the price, the agents involved, and the intended use of proceeds. There is no financial statement or detailed financial analysis present. The document is focused on a capital raising event and the completion of a financing transaction. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other filing types. The length and content confirm it is not a brief announcement of a report publication or a regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-12-31 English
News release - English.pdf
Capital/Financing Update Classification · 70% confidence The document is a press release announcing the expansion of Avicanna's RHO Phyto medical cannabis products into retail channels across Canada. It discusses product launch success, sales strategy, and company background. There is no indication of financial statements, regulatory filings, voting results, or management changes. The content is promotional and informative about business operations and product availability, typical of a Capital/Financing Update or general corporate announcement. However, it does not discuss fundraising, capital structure changes, or financing activities explicitly. It is not a report or transcript but a corporate news announcement. Given the options, the closest fit is Capital/Financing Update (CAP) as it relates to business expansion and product commercialization updates, which often fall under this category in the absence of more specific classifications. Confidence is moderate due to the document's nature as a corporate announcement about product expansion and market strategy.
2020-12-23 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a significant operational milestone: the commissioning of a silicon nano reactor by HPQ Nano, a subsidiary of HPQ Silicium Inc. It discusses the technology, development phases, and future plans but does not contain any financial statements, detailed financial performance data, or regulatory filing references. The document is about a technological and operational update rather than financial results, management changes, or regulatory compliance. It is not a report, transcript, or formal filing but rather a corporate announcement about a product development milestone. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate update, which corresponds to Regulatory Filings (RNS).
2020-12-17 English
Material change report - English.pdf
Regulatory Filings
2020-12-14 English
Underwriting or agency agreement.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'AGENCY AGREEMENT' and details terms related to an offering of units, including pricing, agent fees, over-allotment options, and warrant issuance. It discusses the engagement of agents to sell securities on a best efforts basis, the structure of the offering, and related legal and procedural terms. There is no indication that this is a financial report, earnings release, or regulatory filing per se. Instead, it is a detailed agreement related to capital raising activities. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains detailed terms of the financing arrangement rather than a brief announcement or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2020-12-11 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Avicanna's medical cannabis program in Colombia. It focuses on product offerings, market expansion, educational programs, and company background. There are no financial statements, regulatory filings, voting results, or management changes discussed. The content is promotional and informative about a new business initiative rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The document is best classified as a general corporate announcement about a new program launch, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2020-12-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.